Clinical Necessity Is Required for Compounded GLP-1 Prescriptions Under current 503A regulations, a compounding pharmacy may only prepare semaglutide or tirzepatide formulations that represent a clinically significant difference from the commercially available product
Zhihong Y, Chen W, Qianqian Z, Lidan S, Qiang Z, Jing H, et al
Semaglutide GLP-1 is now recommended by the FDA for chronic weight management in patients with a BMI greater than 30 kg/m2 or 27 kg/m2 but having at least one obesity-related comorbidity
Comprehensive Progress Tracking: The program offers tools to monitor your progress towards your goals, including dietary intake, exercise, weight changes, and other health metrics, helping you stay informed about your journey